Genentech Loses Appeal Of $500M Royalties Verdict
A California appeals court has upheld more than $500 million in damages against biotech company Genentech in a dispute over royalties on human insulin and human growth hormone developed in part...To view the full article, register now.
Already a subscriber? Click here to view full article